Form 4: Zivo Bioscience Director Boosts Stake with $15K Stock Purchase

Zivo Bioscience Director and 10% owner Laith L. Yaldoo acquired 1,766 shares of common stock for $8.49 per share, increasing his indirect beneficial ownership.

Summary

• Laith L. Yaldoo, a Director and 10% owner of Zivo Bioscience, Inc. (ZIVO), purchased shares of the company's common stock.
• The transaction occurred on January 14, 2026.
• Yaldoo acquired 1,766 shares at a price of $8.49 per share.
• The total value of the acquisition was approximately $14,992.34.
• Following this transaction, Yaldoo indirectly beneficially owns 579,638 shares of Zivo Bioscience common stock through HEP Investments LLC.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to a director and significant owner increasing their stake, which typically signals confidence in the company's future. However, the transaction size is not exceptionally large, preventing a higher score.

Positives

• Insider buying by a Director and 10% owner can signal confidence in the company's future prospects and valuation.
• The purchase increases the alignment of management's interests with those of other shareholders.

Risks

• While insider buying is generally a positive signal, it does not guarantee future stock performance or company success.
• The amount purchased, while significant for an individual, is a relatively small percentage of the total shares outstanding and the insider's overall holdings.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Zivo Bioscience's future financial performance or strategic direction.

Industry Context

Insider purchases, particularly by significant stakeholders like directors and 10% owners, are often interpreted by the market as a positive indicator, suggesting that those with intimate knowledge of the company believe its stock is undervalued or poised for growth. This transaction aligns with a general trend where insider sentiment can influence investor perception, especially in smaller cap companies.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, potentially increasing confidence in the company's stock.
• The transaction increases the alignment of interests between the reporting person and other shareholders.

Key Dates

Recommendation

While insider buying is a positive signal, this single transaction, though by a significant insider, is not substantial enough on its own to warrant a 'buy' recommendation without further fundamental analysis of Zivo Bioscience's operations, financials, and market position. It suggests confidence from a key insider, which supports holding existing positions, but does not provide sufficient new information for a strong 'buy' call.

Keywords

Zivo Bioscience, ZIVO, Insider Trading, Form 4, Stock Purchase, Director, 10% Owner, Laith L. Yaldoo, Equity Acquisition